Long-Term Survival of a Patient With Peritoneal Carcinomatosis From Pancreatic Cancer Maintained by Nanoliposomal Irinotecan as Third-Line Chemotherapy

Pancreatic cancer is still one of the most fatal neoplastic diseases, and the recurrence occurs in more than 80% of the patients even though radical resection is performed. We experienced a long-term survival case of a patient with peritoneal carcinomatosis from pancreatic cancer maintained by nanol...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagata, Keiji, Kajiwara, Masatoshi, Fujikawa, Takahisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Gastroenterology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934406/
https://www.ncbi.nlm.nih.gov/pubmed/35317028
http://dx.doi.org/10.7759/cureus.22355
_version_ 1784671841428701184
author Nagata, Keiji
Kajiwara, Masatoshi
Fujikawa, Takahisa
author_facet Nagata, Keiji
Kajiwara, Masatoshi
Fujikawa, Takahisa
author_sort Nagata, Keiji
collection PubMed
description Pancreatic cancer is still one of the most fatal neoplastic diseases, and the recurrence occurs in more than 80% of the patients even though radical resection is performed. We experienced a long-term survival case of a patient with peritoneal carcinomatosis from pancreatic cancer maintained by nanoliposomal irinotecan (nal-IRI) in combination with fluorouracil and folinic acid (FF) as third-line chemotherapy. Nal-IRI + FF combination chemotherapy is one of the promising options for the management of intractable recurrent pancreatic cancer.
format Online
Article
Text
id pubmed-8934406
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-89344062022-03-21 Long-Term Survival of a Patient With Peritoneal Carcinomatosis From Pancreatic Cancer Maintained by Nanoliposomal Irinotecan as Third-Line Chemotherapy Nagata, Keiji Kajiwara, Masatoshi Fujikawa, Takahisa Cureus Gastroenterology Pancreatic cancer is still one of the most fatal neoplastic diseases, and the recurrence occurs in more than 80% of the patients even though radical resection is performed. We experienced a long-term survival case of a patient with peritoneal carcinomatosis from pancreatic cancer maintained by nanoliposomal irinotecan (nal-IRI) in combination with fluorouracil and folinic acid (FF) as third-line chemotherapy. Nal-IRI + FF combination chemotherapy is one of the promising options for the management of intractable recurrent pancreatic cancer. Cureus 2022-02-18 /pmc/articles/PMC8934406/ /pubmed/35317028 http://dx.doi.org/10.7759/cureus.22355 Text en Copyright © 2022, Nagata et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Gastroenterology
Nagata, Keiji
Kajiwara, Masatoshi
Fujikawa, Takahisa
Long-Term Survival of a Patient With Peritoneal Carcinomatosis From Pancreatic Cancer Maintained by Nanoliposomal Irinotecan as Third-Line Chemotherapy
title Long-Term Survival of a Patient With Peritoneal Carcinomatosis From Pancreatic Cancer Maintained by Nanoliposomal Irinotecan as Third-Line Chemotherapy
title_full Long-Term Survival of a Patient With Peritoneal Carcinomatosis From Pancreatic Cancer Maintained by Nanoliposomal Irinotecan as Third-Line Chemotherapy
title_fullStr Long-Term Survival of a Patient With Peritoneal Carcinomatosis From Pancreatic Cancer Maintained by Nanoliposomal Irinotecan as Third-Line Chemotherapy
title_full_unstemmed Long-Term Survival of a Patient With Peritoneal Carcinomatosis From Pancreatic Cancer Maintained by Nanoliposomal Irinotecan as Third-Line Chemotherapy
title_short Long-Term Survival of a Patient With Peritoneal Carcinomatosis From Pancreatic Cancer Maintained by Nanoliposomal Irinotecan as Third-Line Chemotherapy
title_sort long-term survival of a patient with peritoneal carcinomatosis from pancreatic cancer maintained by nanoliposomal irinotecan as third-line chemotherapy
topic Gastroenterology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934406/
https://www.ncbi.nlm.nih.gov/pubmed/35317028
http://dx.doi.org/10.7759/cureus.22355
work_keys_str_mv AT nagatakeiji longtermsurvivalofapatientwithperitonealcarcinomatosisfrompancreaticcancermaintainedbynanoliposomalirinotecanasthirdlinechemotherapy
AT kajiwaramasatoshi longtermsurvivalofapatientwithperitonealcarcinomatosisfrompancreaticcancermaintainedbynanoliposomalirinotecanasthirdlinechemotherapy
AT fujikawatakahisa longtermsurvivalofapatientwithperitonealcarcinomatosisfrompancreaticcancermaintainedbynanoliposomalirinotecanasthirdlinechemotherapy

Ejemplares similares